We prefer the outlook for J&J

Article Excerpt

Medical products giant Johnson & Johnson first sold shares in its consumer drug business, Kenvue, to the public in May 2023 at $22.00 a share. Johnson & Johnson later let its own shareholders exchange JNJ shares for Kenvue shares at a 7% discount. The company held onto 9.5% of Kenvue, which it will likely sell in the next few months. So far, Johnson & Johnson shares are down 5%, while Kenvue is down 14%. We feel both stocks will benefit from the split, but prefer the former parent for your new buying, particularly as it moves closer to settling claims that its talc baby powder causes ovarian cancer. JOHNSON & JOHNSON $156 is a spinoff buy. The company (New York symbol JNJ; Manufacturing sector; Shares outstanding: 2.4 billion; Market cap: $374.4 billion; Dividend yield: 3.1%; Takeover Target Rating: Medium; www.jnj.com) is an American multinational corporation that develops medical devices and pharmaceuticals. On November 30, 2023, Johnson & Johnson’s Medtech division announced that it had completed its acquisition…